highlight the updated list of biotech and pharmaceutical companies with FDA drug approval decisions expected for the remainder of 2013.
The next era of hepatitis C therapy could begin on Dec. 6, if FDA approves Gilead's sofosbuvir. Amarin is hoping FDA approves an expanded label for its prescription-grade fish oil pill Vascepa on Dec. 20.
aren't on the list but are still very much in the investor spotlight. Sarepta and FDA are still going back and forth over the the company's request to file an accelerated approval application for eteplirsen to treat Duchenne muscular dystrophy. We may have some resolution early in the third quarter.
Pharmacylics and partner
Johnson & Johnson
are expected to seek FDA approval for their blood-cancer drug ibrutinib before the end of the third quarter. FDA has already annointed ibrutinib with multiple breakthrough therapy designations, so it makes sense for the agency to approve the drug quickly. Is an ibrutinib approval before year end a possibility? I think so, in fact, I'd say the Street expects an early approval.
Let's not forget the importance of European drug approvals. Here are the dates for the remaining Committee for Medicinal Products for Human Use (CHMP) meetings in 2013:
May 27-30; June 24-27; July 22-25; Aug. 19-22; Sept. 16-19; Oct. 21-24; Nov. 18-2; and Dec. 16-19.
The most closely watched, upcoming European drug approval decisions include
(Provenge, prostate cancer);
(Juxtapid, homozygous familial hypercholesterolemia) and
(Pomalyst, multiple myeloma.)
Biotech and drug stocks below are listed in chronological order based on the closest regulatory catalyst -- FDA drug approval decisions and advisory panels.
Drug/indication: Suvorexant for insomnia
FDA advisory panel: May 22
Approval decision date: June-July
Drug/indication: Efinaconazole, toe-nail fungus
Approval decision date: May 23
Drug/indication: Sefelsa, menopause
Approval decision date: May 31
Drug/indication: Zohydro, chronic pain
Approval decision date: Summer
Drug/indication: Dabrafenib, melanoma
Approval decision date: June 3
Drug/indication: Tivozanib, kidney cancer
Approval decision date: July 26
Drug/indication: Dolutegravir, HIV
Approval decision date: Aug. 17
Drug/indication: Trametenib, melanoma
Approval decision date: Sept. 3
Drug/indication: Xiaflex, Peyronie's Disease
Approval decision date: Sept. 6
Drug/indication: Meblez, liver tumors due to ocular melanoma
Approval decision date: Sept. 13
Drug/indication: Adcetris, retreatment of Hodgkin's lymphoma
Approval decision date: Sept. 14
Drug/indication: Otrexup, rheumatoid arthritis
Approval decision date: Oct. 14
Drug/indication: Iluvien, diabetic macular edema
Approval decision date: Oct. 17
Drug/indication: Feraheme, iron deficient anemia
Approval decision date: Oct. 21
Drug/indication: Entereg, post-operative constipation
Approval decision date: Oct. 21
Drug/indication: Sofosbuvir, hepatitis C
Approval decision date: Dec. 6
Drug/indication: Vascepa, mixed dyslipidemia
Approval decision date: Dec. 20
Calendar compiled with assistance from BioMedTracker, company reports and TheStreet research.
-- Reported by Adam Feuerstein in Boston.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.